Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

| More on:

Young African Businesswoman Analyzing Data On Multiple Computer Screen In Office

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It has been another busy week for Australia's top brokers. This has led to the release of a large number of broker notes.

Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these ASX shares are in the buy zone:

ANZ Group Holdings Ltd (ASX: ANZ)

According to a note out of Goldman Sachs, its analysts have upgraded this banking giant's shares to a buy rating with a $27.38 price target. The broker has also added ANZ to its coveted conviction list and crowned it as the best big four bank to buy now. This is based on its confidence in the sustainability of ANZ's improvement in its Institutional returns. The ANZ share price is trading at $23.61 on Friday afternoon.

Paladin Energy Ltd (ASX: PDN)

A note out of Macquarie reveals that its analysts have retained their outperform rating and $1.10 price target on this uranium developer's shares. This follows an update on its progress in restarting the Langer Heinrich uranium mine. Macquarie was pleased that the company remains on course to restart production in the first quarter of 2024. This bodes well for Paladin given the increasing demand for uranium and tight market conditions. The Paladin Energy share price is fetching 74 cents today.

Telix Pharmaceuticals Ltd (ASX: TLX)

Analysts at Bell Potter have retained their buy rating and $14 price target on this radiopharmaceutical company's shares. Bell Potter was pleased with the company's recent acquisition of the Dedicaid AI platform for nuclear medicine. It feels this could put the company at the forefront of plugging a gap in the US market. The Telix share price is trading at $11.29 today.

Motley Fool contributor James Mickleboro has positions in Telix Pharmaceuticals. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

watch
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Mum playing with her baby boy holding him on her tummy as she lays down while smiling about the Bubs share price going up today
Broker Notes

Following two unfortunate incidents, what's Macquarie's price target on Monash IVF shares?

Is Monash IVF a buying opportunity?

Read more »

A happy male investor turns around on his chair to look at a friend while a laptop runs on his desk showing share price movements
Broker Notes

Macquarie tips 18% return for this ASX 200 stock

The broker thinks this blue chip's profits are going to rebound in FY 2026.

Read more »

Three happy office workers cheer as they read about good financial news on a laptop.
Broker Notes

Bell Potter names more of the best ASX 200 shares to buy in FY26

These shares are among the best to buy in the new financial year according to its analysts.

Read more »

Suncorp share price Businessman cheering and smiling on smartphone
Broker Notes

5 ASX 200 shares for smart investors to buy in July

Brokers think these shares could be in the buy zone ahead of the new month.

Read more »

A group of businesspeople clapping.
Broker Notes

Bell Potter names the best ASX 200 shares to buy in FY26

The broker has good things to say about these shares.

Read more »

Man on his laptop standing next to data centres.
Broker Notes

Macquarie tips 54% upside for NextDC shares

NextDC shares certainly have momentum.

Read more »

Two lab workers fist pump each other.
Broker Notes

What's JP Morgan's price target on CSL shares?

Are CSL shares undervalued or will they continue to underperform?

Read more »